Sanofi invests billions into Frankfurt insulin production site

French pharmaceutical company Sanofi have announced an investment of EUR1.3 billion at their existing BioCampus site in Frankfurt am Main for the expansion of insulin production. 

The expansion will include an additional 36,000 square metres to the existing facility and is expected to be operational by 2029. The project is partly support by the German national government and the government of the regional state of Hesse pending EU approval. As one of the leading global producers of insulin, the German government hopes this investment will bolster pharmaceutical R&D in the country, priming the nation as a leading pharmaceutical hub. 

“The Sanofi expansion is great news for Germany as a pharmaceuticals location and an expression of Germany’s past and future strength in the area,” commented Robert Hermann, Germany Trade & Invest CEO. “The German government sees pharma as an economic pillar in the years to come, and the incentives and reforms it has promoted are encouraging some of the biggest names in the global industry to put their faith in the country.” 

The German national government officially adopted a pharmaceutical strategy in 2023 intended to bolster support for global companies to streamline approval and improve R&D conditions in Germany. This strategy has attracted the likes of Eli Lilly, Daiichi-Sankyo, and Roche into investing in their own billion-euro ventures in the country. “There’s every reason to expect that more and more international companies will follow suit,” stated Hermann. 

“With this project, we reaffirm our commitment to help diabetes sufferers around the world,” said Brendan O’Callaghan, Global Head of Manufacturing & Supply at Sanofi. “We’re using the long-time expertise of our Frankfurt BioCampus and its highly qualified personnel.” 

Heidrun Irschik-Hadjieff, chairman of Sanofi in Germany, added “Our planned investment underscores the central role played by the Frankfurt BioCampus in strengthening the resilience of global insulin production. The strong support of both the national and regional German governments is a powerful signal for the biopharmaceutical industry.” 

Source: 

Germany attracts another billion-euro pharma project [Accessed August 2, 2024] https://www.prnewswire.com/news-releases/germany-attracts-another-billion-euro-pharma-project-302212375.html